2X Blend — CJC-1295 Without DAC / Ipamorelin

The 2X Blend is a co-formulation of CJC-1295 without DAC and Ipamorelin, two synthetic peptides known for their distinct yet complementary actions on the growth hormone secretagogue receptor (GHSR) and growth hormone-releasing hormone (GHRH) pathways. CJC-1295 without DAC is a modified GHRH analog that acts by stimulating the pituitary gland to release growth hormone. Its structure is characterized by specific amino acid substitutions that enhance its stability and biological activity, though it lacks the Drug Affinity Complex (DAC) modification present in other variants, resulting in a shorter half-life suitable for acute experimental observations. Ipamorelin, a selective growth hormone secretagogue, functions as a ghrelin mimetic, binding to the GHSR. This interaction leads to a pulsatile release of growth hormone without significantly affecting levels of other pituitary hormones such as prolactin, adrenocorticotropic hormone (ACTH), or cortisol. The combination of these two peptides in the 2X Blend allows for comprehensive studies into the complex interplay between GHRH and ghrelin signaling pathways in the regulation of growth hormone secretion. Research applications include exploring pituitary function, metabolic regulation, and neuroendocrine signaling. Historically, research into growth hormone regulation has involved various synthetic secretagogues. The development of peptides like CJC-1295 and Ipamorelin has provided valuable tools for dissecting these intricate biological processes. This blend facilitates investigations into the mechanisms underlying growth hormone release, offering a controlled experimental system for studying the effects of combined GHRH and GHSR agonism. Researchers can utilize this blend to explore cellular signaling cascades, receptor kinetics, and physiological responses in relevant research models.